Feed/Companies/Tune Therapeutics

Tune Therapeutics

As of 14 Oct 2026, Tune Therapeutics has raised $175M across 1 verified round on record; latest: $175 million Series B led by Hevolution Foundation, New Enterprise Associates and 2 others, announced 13 Jan 2025.

BUILT ON

Visit site

TuneTx sells genetic tuning technology aimed at transforming health through gene and regenerative therapies, targeting diseases at their source.

tunetx.comLinkedInBiotech

LATEST ROUND

Series B

$175M · 2025-01-13

RAISED ON RECORD · USD

$175M

across 1 verified round

INVESTORS

4 leads

SOURCES

from 1 publisher

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$175M · 2025-01-13

[ HISTORY ]

led by Hevolution Foundation, New Enterprise Associates, Regeneron Ventures, Yosemite

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$175M	2025-01-13	Hevolution Foundation, New Enterprise Associates, Regeneron Ventures, Yosemite	No recent discussion
1 source [ VERIFIED ] read against 1 source The source describes the financing as led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation; no other round participants, valuation, or financing total is stated. Published by hand (fiercebiotech.com): "Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic.": biggest-rounds completeness (K): hand-checked, the cited page states $175 million

Tune Therapeutics

Company

Rounds

Sources

Profile

Investors

Tune Therapeutics

Rounds

Profile

Sources

Series B$175M2025-01-131 source

Investors

Series B$175M2025-01-134 investors